AUTHOR INDEX

VOLUME 49

Abramczuk, Jan, 540
Amati, Paolo, 566
Anderson, Carl W., 692, 873
Anderson, Steven M., 881
Arsenakis, Minas, 813
Aschman, Doris P., 236
Auer, Bernhard, 588

Babiss, Lee E., 731
Bacchetti, S., 591
Bacchetti, Silvia, 162
Bakker, Anke, 343
Balce-Directo, L., 279
Baltimore, David, 269, 686
Banerjee, Papiya T., 319
Barisas, B. George, 980
Basilico, Claudio, 984
Bates, Robert C., 315, 319, 652
Bauer, William R., 1
Bayne, Marvin L., 333
Beckson, Mace, 881
Bedigian, Hendrick G., 437
Beigel, Michel, 1009
Bellini, William J., 988
Benatre, A., 325
Benbow, Robert M., 333
Ben-Porat, Tamar, 970
Berk, Arnold J., 132
Bestwick, Richard K., 394
Bizub, Diane, 557
Blank, Kenneth J., 14
Blankenhorn, Elizabeth P., 14
Blankenship, Mayme Lee, 970
Boettiger, David, 841
Boeye, A., 1002
Bouck, Noel, 997
Bouloy, M., 717
Branton, Philip E., 162
Braun, Daniel K., 142
Brow, Mary Ann D., 579
Brown, Arthur, 379
Brown, Dale D., 1018
Bryniok, Dieter, 20
Buonagurio, Deborah A., 418
Burghoff, Robert L., 343
Burny, Arsene, 615
Butel, Janet S., 50

Calenoff, Miriam, 262
Callahan, Robert, 1005
Calothy, G., 325
Cardiff, Robert D., 66
Carter, V. Celeste, 766
Champoux, James J., 686
Chejanovsky, Nor, 1009
Christie, T., 229
Clark, B. R., 279
Clements, Janice, 349
Cloyd, Miles W., 772
Coen, Donald M., 236
Cohen, G., 287
Cohen, G. H., 102
Cohen, Gary H., 265
Cole, Michael D., 171
Colicelli, John, 918
Collins, Peter L., 572
Compton, Teresa, 594
Concannon, Patrick, 276
Condit, Richard C., 125
Cook, K. Anne, 57
Copeland, Neal G., 437
Costa, R. H., 287
Cote, Paul J., 701
Couez, Dominique, 615
Courtney, Richard J., 594
Crawford, Sarah, 909
Crowell, Richard L., 635
Cummings, Ian W., 276
Cywinski, Anita, 200
Czarniecki, Christine W., 490

Dailey, Lisa, 984
Daillie, J., 626
Dambrine, G., 325
Darai, G., 609
Davis, Nancy L., 303
DeBorde, Dan C., 418
DeClercq, Erik, 205
Delius, H., 609
Delli Bovi, Pasquale, 566
DeLucia, Angelo L., 9
Deschamps, Jaqueline, 615
De Simone, Vincenzo, 566
de Soriano, Imelda Lindo, 409
Desrosiers, Ronald C., 343, 938
de The, G., 626
de Turenne, M., 626
Dezelee, P., 325
Dietzschold, B., 102
Drexler, Henry, 754
Dudley, Jaquelin, 92
Durban, Elisa, 841

Eckhart, Walter, 799
Ehrlich, Melanie, 674
Eisenberg, R., 287
Eisenberg, R. J., 102
Eisenberg, Roselyn J., 265
Ellis, Ronald W., 601
Engle, Ronald E., 701
Esnault, E., 325
Estell, David A., 490
Evans, Leonard H., 772
Evelegh, M. J., 591

Faller, Douglas V., 269
Fanning, Thomas G., 66
Faust, Emanuel A., 621
Fennie, Christopher W., 490
Ferrer, Jorge F., 583
Fields, Bernard N., 641
Fikes, John, 997
Fisher, P. B., 731
Fleckenstein, Bernhard, 109, 363, 938
Flügel, R. M., 609
Foglesong, P. David, 1
Freshney, Mary, 253
Friedrich, Roland, 828
Friedrichs, William E., 992
Friesen, Paul D., 116
Fukui, Yasuhisa, 154

Galibert, Francis, 782
Gallahan, Daniel, 1005
Galloway, Denise A., 109, 724
Gao, Min, 426
Gelep, Paul T., 236
Gentsch, Jon R., 641
Gerin, John L., 701
Gilboa, Eli, 686
Gilden, Raymond V., 615
Ginsberg, H. S., 731
Giordano, Roberto, 566
Girard, M., 717
Gloor, Greg, 621
Glorioso, Joseph C., 947
Goff, Stephen P., 909, 918
Goldberg, Barbara, 635
Goldin, Alan L., 947
Golini, Fred, 459
Golub, E., 102
Goorha, Rakesh, 86
Gope, Rajalakshmi, 293
Gordon, Marc L., 918
Gourlie, Brian B., 333
Graham, Dale E., 819
Graham, Frank L., 162
Granoff, Allan, 86
Graves, Michael, 409
Gregoriades, A., 229
Griffin, Diane E., 349, 409
Grose, Charles, 992
Grubman, Marvin J., 760
Gruss, Peter, 183
Gunnell, Mark A., 297

Halbert, Donald N., 692
Hanafusa, Hidesaburo, 549, 881
Hänggi, Markus, 371
Hassell, John A., 925
Hays, William W., 604
Hearing, Patrick, 692
Heller, Knut J., 20
Henning, Roland, 658
Herr, Winship, 471
Hess, Jay, 349
Hiller, Gerhard, 371
Hirai, Kanji, 1014
Hirsch, Robert L., 409
Hogue-Angeletti, Ruth, 265
Holland, John J., 793
Holland, Louis E., 947
Honnen, William J., 452
Horisberger, Michel A., 709
Horodyski, Frank M., 793
Hu, Shiu-Lok, 604
Hu, Wei-Shau, 66
Huang, Yung T., 572
Hummel, Mary, 413
Huszar, D., 591

Ikuta, Kazuyoshi, 1014
Innis, Michael A., 629
Isom, Harriet C., 426

Jahn, Gerhard, 109, 363
Jasmin, Claude, 253
Jenkins, Nancy A., 437
Jennings, Stephen R., 766
Johnson, Richard T., 409
Jones, Elaine V., 72
Jullien, P., 325

Kääriäinen, Leevi, 403
Kabat, David, 394
Kamine, James, 343
Karamata, Dimitri, 806
Kashmiri, S. V. S., 583
Kates, Joseph R., 459
Kato, Shiro, 1014
Katz, Richard A., 557
Kay, Alan, 782
Keller, Beat, 902
Kettmann, Richard, 615
Kew, Olen M., 873
Khoury, George, 183
Kieff, Elliott, 413
Klessig, Daniel F., 35
Knipe, David M., 960
Knowles, Barbara B., 540
Knust, Elisabeth, 363
Koch, Werner, 828
Kohler, Martin, 658
Kolakofsky, Daniel, 680
Kozak, Christine, 297, 1005
Krauss, Marc R., 333
Krystal, Mark, 418
Kuhn, Andreas, 902

Labedan, Bernard, 273
Lai, Ching-Juh, 223
Laimins, Laimonis A., 183
Langer, Charlotte A., 701
Lederman, Muriel, 315
Lerner, Teena L., 549
Leuther, Michael D., 980
Levine, Arnold J., 692
Levine, Myron, 947
Lewton, Betsy A., 9
Lomniczi, Bela, 970
London, William, 848
Long, D., 102, 287
Long, Deborah, 265
Low, Robert L., 178
Lowy, Douglas R., 601
Loyter, Abraham, 1009

Maassab, H. F., 418
Machida, Curtis A., 394
Mackett, Michael, 857
Maeder, Marlies, 892, 902
Maeno, Koichiro, 598
Mahr, Anna, 497, 510
Mandart, Elisabeth, 782
Mangel, Walter F., 445
Maniloff, Jack, 283
Margolskee, Robert F., 386
Mark, George E., 530
Markarian, K., 229
Markoff, Lewis J., 223
Maruyama, Kazuo, 479
Maul, Gerd, 540
Mauël, Catherine, 806
McDougall, James K., 109, 363
McFarland, Henry F., 988
McFarlin, Dale E., 988
McKeever, Paul E., 848
Medina, Daniel, 819
Mehdi, Rafia, 583
Meyer, Thomas, 709
Miller, A. Dusty, 214
Miller, Nancy R., 848
Mitra, Sankar, 319
Monroe, Stephan S., 865
Montenarh, Mathias, 658
Moss, Bernard, 72, 857

Muirhead, B., 591
Müller, Ingrid, 938
Murphy, Brian R., 248

Narayan, Opendra, 349
Nathans, Daniel, 386
Nelson, Jay A., 109, 363
Nichol, Stuart T., 793
Nishiyama, Yukihiro, 598
Nunberg, Jack H., 629

Oda, Kinichiro, 479
O'Hara, Patrick J., 793
Oker-Blom, Christian, 403
Oliff, Allen, 828
Omilianowski, Daniel R., 873
Ooka, T., 626
Ostertag, Wolfram, 253

Padgett, Billie L., 848
Palese, Peter, 418
Pallansch, Mark A., 873
Pan, Sueihua, 540
Pardigon, N., 717
Patterson, Jean L., 680
Patton, John T., 303, 315
Pellegrini, Sandra, 984
Penn, Linda J. Z., 748
Pereira, L., 102
Pereira, Lenore, 142
Petrie, Betty L., 665
Pettersson, Ralf F., 403
Pinter, Abraham, 452
Poddar, Saibal K., 283
Poirier, F., 325
Pomerantz, Betsy J., 925
Ponce de Leon, M., 102
Ponzetto, Antonio, 701
Potts, Diane E., 604
Powers, David B., 490
Pozzatti, Rudy, 183

Rabin, Mark, 445
Rafield, Lori F., 960
Ramig, Robert F., 665
Rapp, Fred, 205
Rapp, Ulf R., 297, 530
Ray, Dan S., 178
Reagan, Kevin J., 635
Reck, Linda J., 248
Renz, Christopher, 262
Retondo, Margaret J., 236
Rice, Patricia L., 766
Rice, Stephen A., 35
Risser, Rex, 92
Roberts, Bryan E., 125, 497, 510
Robertson, Alice T., 652
Roedenbeck, Susi, 409
Roizman, Bernard, 142, 813
Rombaut, B., 1002
Rose, John W., 988
Rosenthal, Ken S., 980
Rosser, Debra S. E., 132
Rowe, David T., 162
Rueckert, Roland R., 116, 873
Rundell, Kathleen, 262
Rundell, M. Kathleen, 997
Rutter, Gabriel, 253

Saito, Izumu, 154
Salser, Winston A., 276
Salzman, Lois A., 1018
Sandri-Goldin, Rozanne M., 947
Santos, Myriam, 50
Sarnow, Peter, 692
Sarre, Thomas, 363
Sartori, C. S., 591
Schaffer, Priscilla A., 236
Scheck, Adrienne C., 205
Schirm, Sabine, 938
Schlesinger, Sondra, 865
Schmolla, Henrik, 363
Schwartzberg, Pamela, 918
Schweiger, Manfred, 588
Scolnick, Edward M., 601
Semler, Bert L., 873
Sen, Arup, 579
Serwer, Philip, 293
Sheffer, Darlene, 349
Shenk, Thomas, 692
Shen-Ong, Grace L. C., 171
Shenoy, Suresh, 674
Shimojo, Hiroto, 154
Shinomiya, Tomoyuki, 310
Shiroki, Kazuko, 154
Skalka, Anna Marie, 557
Smiley, James R., 356
Smith, Geoffrey L., 857
Smith, Gilbert H., 819
Smith, Julie K., 200
Snyder, Cathy E., 319
Spear, Patricia G., 741
Spindler, Katherine R., 132
Sridhar, P., 125
Steffensen, Dale M., 445
Stenberg, Richard M., 190
Stephens, Robert M., 615
Stewart, Charles R., 300
Stinski, Mark F., 190
Stout, Ernest R., 315, 652
Strathearn, Michael D., 178
Sutcliffe, J. Gregor, 579
Sveda, Michael M., 223
Swain, Margaret A., 724

Taylor, John M., 200
Tegtmeyer, Peter, 9
Temin, Howard M., 521
Templeton, Dennis, 799
Tevethia, Satvir S., 766
Thomas, Christopher Y., 437
Thomsen, Darrell R., 190
Thorley-Lawson, David, 413
Ting, Y.-P., 279
Traktman, Paula, 125
Traub, Franz, 892, 902

Udem, Stephen A., 57
Ueda, Shigeharu, 1014
Uhlenbeck, Olke C., 445
Ulmanen, Ismo, 403

Vaisberg, Abraham, 409
van Wyke, Kathleen L., 248
Varmuza, Susannah L., 356
Varrichio, A., 102
Vehmeyer, Katalin, 253
Verma, Inder M., 214
Vialat, P., 717
Vrijsen, R., 1002

Wagner, E., 287
Walker, Duard L., 848
Wallen, William C., 848
Wang, Lu-Hai, 881
Wang, Richard Y.-H., 674
Watanabe, Sumie, 78
Weissbach, Arthur, 26
Weller, Sandra K., 236
Wertz, Gail W., 303, 572
Wigdahl, Brian, 205, 426
Wilhelmsen, Kirk C., 521
Williams, Bryan R. G., 748
Williams, Mark E., 629
Willis, Dawn B., 86
Willumsen, Berthe M., 601
Wimmer, Eckard, 873
Wing, David, 26
Wittek, Riccardo, 371
Wolcott, Judith A., 379
Wolfe, John H., 14
Wust, Carl J., 379

Yee, Sui-Pok, 162
Yewdell, Jonathan W., 248
Yogo, Yoshiaki, 78
Yoshida, Shonen, 598
Yoshiike, Kunito, 78

Zaia, J. A., 279
Zezulak, Kathleen M., 741
Ziegler, Richard J., 205
Zimmermann, Wolfgang, 828

SUBJECT INDEX
VOLUME 49

Adenovirus
12
transformation-defective, replication-nondefective early region 1B mutants, 154
5
cold-sensitive phenotype for transformation, 731
defective phenotype for transformation, 731
deletion mutations, 731
early region 1a deletion mutations, 731
early region 1a insertion mutations, 731
hamster cell lines, 162
insertion mutations, 731
restriction endonuclease fragments, 162
transformation, 731
DNA-binding protein
viral late gene expression, 35
early region 4
25,000-dalton protein, 692
early region 1B 58,000-dalton tumor antigen, 692
productively infected cells, 692
early region 1A
transforming proteins, 132
early region 1B
58,000-dalton tumor antigen, 692
early region 4 25,000-dalton protein, 692
productively infected cells, 692
transforming proteins, 132
productively infected cells
early region 1B 58,000-dalton tumor antigen, 692
early region 4 25,000-dalton protein, 692
transforming proteins
early region 1A, 132
early region 1B, 132
E. coli fusion antigens, 132
viral DNA replication, 35
AKV murine leukemia virus
nucleotide sequence, 471
Antibody
measles virus, 409
monoclonal
herpesvirus of turkeys, 1014
influenza A virus, 248
Marek's disease virus, 1014
neutralizing
caprine arthritis-encephalitis lentivirus, 349
herpes simplex virus, 102
nonneutralizing, monoclonal
poliovirus, 1002
Antigen
fusion
E. coli, 132
herpes simplex virus, 102
influenza A virus, 248
large T
polyomavirus, 925
simian virus 40, 658, 925, 997
large tumor
simian virus 40, 50
O
bacteriophage T5, 20
small-t
simian virus 40, 262
surface
woodchuck hepatitis virus, 701
T
simian virus 40, 386
tumor
adenovirus, 692
Aphidicolin
inhibition of bovine parvovirus replicative-form DNA, 652
ATP
effects on vaccinia virus type I topoisomerase activity, 1
Avian myeloblastosis virus
embryonic yolk sac
relationship of cell differentiation to cell transformation, 841
target cells, 841
reverse transcriptase
RNA primer removal, 686
RNase H activity, 686
target cells
embryonic yolk sac, 841
relationship of cell differentiation to cell transformation, 841
Avian retrovirus
genome
plus-strand DNA synthesis, 200
reverse transcription, 200
Avian sarcoma virus
recovered
viral sequence required for generation, 881
replication-defective recovered, 881

Bacillus subtilis
mitomycin C
proteins, 806
proteins
mitomycin C, 806
Bacteriophage
ϕX174
DNA methylation, 674
DNA single-strand initiation determinant, 178
replicative-form DNA, 178
transfecting activity of replicative-form DNA, 674
λ
initiation of DNA packaging by bacteriophage T1, 754
P gene, 754
Q gene, 754
P22
capsids with subgenome length of packaged DNA, 293
PS17
P. aeruginosa PAO, 310
pyocin R2, 310
SPO1
double mutant HA20, 300
T1
bacteriophage λ *P* gene, 754
bacteriophage λ *Q* gene, 754
initiation of bacteriophage λ DNA packaging, 754
T4
cross-linking, 902
prohead core formation in vivo, 892
prohead core isolation, 902
protein composition, 902
T5
O antigen-dependent mutant, 20
Black beetle virus
early and late functions
translational control by competition between viral mRNAs, 116
Bovine adenovirus
sequence homology with human adenovirus, 604
Bovine leukemia virus
covalently closed circular DNA
molecular cloning, 583
integrated provirus DNA long terminal repeat
nucleotide sequence analysis, 615
viral and host sequences adjacent to long terminal repeat
nucleotide sequence analysis, 615
Bovine parvovirus
aphidicolin
inhibition of replicative-form DNA, 652
replicative-form DNA
inhibition by aphidicolin, 652
virally coded noncapsid protein, 315

Caprine arthritis-encephalitis lentivirus
immunization
inactivated *M. tuberculosis*, 349
M. tuberculosis
immunization, 349
neutralizing antibodies, 349
persistently infected goats, 349
neutralizing antibodies
immunization with inactivated *M. tuberculosis*, 349
persistently infected goats, 349
persistently infected goats
immunization with inactivated *M. tuberculosis*, 349
neutralizing antibodies, 349
Cell lines
hamster
adenovirus 5, 162
lymphoid
H. saimiri, 938
transformed hybrid
simian virus 40, 445
tumor
derived from *H-2* congenic mice, 14
Gross virus-induced, 14
Cells
Friend erythroleukemic
polyomavirus growth and persistence, 566
HeLa
infected nuclei, 26
vaccinia virus RNA polymerase, 26
human peripheral blood mononuclear
influenza virus vaccine, 748
interferon, 748
rubella virus vaccine, 748
2-5A synthetase activity, 748

nonproducer Raji
DNase, 626
Epstein-Barr virus, 626
rat 3Y1
human papovavirus BK, 78
rhabdomyosarcoma
coxsackievirus B3, 635
T
endogenous mouse mammary tumor virus genomes, 92
mouse lymphomas, 92
target
avian myeloblastosis virus, 841
embryonic yolk sac, 841
herpes simplex virus type 2, 766
lysis by herpes simplex virus-specific cytotoxic T lymphocytes, 766
relationship of cell differentiation to cell transformation, 841
transformed
simian virus 40, 50
transformed mouse
reversion, 479
simian virus 40, 479
Chromosomes
mouse 12
BALB/c, 1005
mouse mammary tumor virus, 1005
mouse 6
BALB/c, 1005
c-*raf* oncogene, 297
mouse mammary tumor virus, 1005
Coliphage
T5
fluid host cell membrane, 273
Coxsackievirus
B3
altered receptor specificity, 635
rhabdomyosarcoma cells, 635

Defective-interfering particles
vesicular stomatitis virus
resistant mutants, 793
Dithiothreitol
Sendai virus
dissociation of adsorbed virus particles from cell membranes, 1009
DNase
Epstein-Barr virus, 626
nonproducer Raji cells, 626
Duck hepatitis B virus
cloned genome
comparison of nucleotide sequence with human hepatitis B virus sequence, 782
comparison of nucleotide sequence with woodchuck hepatitis B virus sequence, 782
nucleotide sequence, 782

Encapsidation
autonomous parvovirus LuIII
minus-strand DNA, 319
plus-strand DNA, 319
Epstein-Barr virus
DNA fragment
envelope glycoprotein gp220/200, 413
envelope glycoprotein gp350/300, 413
DNase activity
nonproducer Raji cells, 626
sodium butyrate treatment, 626
12-*O*-tetradecanoylphorbol-13-acetate treatment, 626
envelope glycoproteins
encoding of messages by DNA fragment, 413
gp220/200, 413
gp350/300, 413
nonproducer Raji cells
DNase activity, 626
sodium butyrate treatment, 626
12-*O*-tetradecanoylphorbol-13-acetate treatment, 626
sodium butyrate treatment
DNase activity, 626
nonproducer Raji cells, 626
12-*O*-tetradecanoylphorbol-13-acetate treatment
DNase activity, 626
nonproducer Raji cells, 626
Escherichia coli
fusion antigens
adenovirus transforming proteins, 132
interferon
human alpha, 490
human beta, 490
human gamma, 490
synergistic antiviral and antiproliferative activities, 490
Escherichia coli virus
T1
DNA methyltransferase, 588

Feline leukemia virus
subgroup B
envelope gene nucleotide sequence, 629
Fibroblasts
human diploid
herpes simplex virus genome, 205
Foot-and-mouth disease virus
in vitro morphogenesis, 760
Friend mink cell focus-inducing virus
envelope gene
molecular analysis, 828
long terminal repeat
molecular analysis, 828
Friend murine leukemia virus
dual-tropic
gp70 specific domains, 452
ecotropic
gp70 specific domains, 452
mink cell focus-forming viruses
recombination with specific endogenous proviral sequences, 772
Frog virus 3
DNA methyltransferase, 86

Germiston bunyavirus
S segment transcript
coding for nonstructural protein, 717
coding for nucleoprotein, 717
uncapped, 717
Goats
caprine arthritis-encephalitis lentivirus
immunization, 349
immunization
caprine arthritis-encephalitis lentivirus, 349
Gross virus
H-2 congenic mice
p30-related proteins, 14
p30-related proteins
H-2 congenic mice, 14
tumor cell lines, 14
tumor cell lines
p30-related proteins, 14
Guinea pig cytomegalovirus
characterization of DNA, 426

Hamsters
cell lines
adenovirus 5, 162
Harvey murine sarcoma virus
p21 v-*ras* gene
transforming sequences, 601
Hemagglutinin
influenza virus
altered hydrophobic carboxy terminus, 223
intracellular accumulation, 223
influenza virus A/USSR/90/77
gene nucleotide sequence, 276
Herpes simplex virus
1
DNA binding, 813
host protein, 813
post-α gene function, 813
antigenic determinant
glycoprotein D, 102
binding
modulation of cell surface protein mobility, 980
capsids
gene 35 protein binding, 142
cell surface protein mobility
modulation by viral binding, 980
modulation by viral entry, 980
DNA diploid region
unstable heterozygosity, 356
DNA polymerase locus
fine mapping of mutations, 236
molecular cloning of mutations, 236
entry
modulation of cell surface protein mobility, 980
gene 35 proteins
binding to full capsid surfaces, 142
nonbinding to empty capsid surfaces, 142
post-translational products, 142
genome
human diploid fibroblasts, 205
in vitro latency, 205
rat sensory neurons, 205
glycoprotein D
antigenic determinant, 102
neutralizing antibody, 102
neutralizing antibody
glycoprotein D, 102
type 1
DNA-binding protein ICP8, 960
genetic analysis of genome, 947
glycoprotein B, 960
glycoprotein C, 741
glycoprotein D amino-terminal sequence, 265
herpes simplex virus type 2 glycoprotein C counterpart, 741
herpes simplex virus type 2 mutant not expressing glycoprotein C, 741
6-kilobase mRNA, 287
major capsid protein VP5, 287

major mRNAs, 960
nuclear fractions, 594
polypeptides, 591
transcriptional analysis of genome, 947
viral ribonucleotide reductase activity, 591
virus-specific glycoproteins, 594
type 2
*Bgl*II N fragment, 724
cytotoxic T lymphocytes, 766
glycoprotein D amino-terminal sequence, 265
herpes simplex virus type 1 glycoprotein C, 741
mutant not expressing glycoprotein C, 741
polypeptides, 591
structural gene mapping, 741
target cell susceptibility to lysis, 766
viral ribonucleotide reductase activity, 591
UV-irradiated
DNA polymerase α, 598
host cell reactivation, 598
Herpesvirus
turkeys
glycoproteins, 1014
monoclonal antibodies, 1014
virus neutralization, 1014
Herpesvirus saimiri
in vitro transformation
lymphoid cell line, 938
lymphoid cell line
in vitro transformation, 938
replication-competent deletion mutants, 343
Host cell reactivation
herpes simplex virus, 598
Human adenovirus
sequence homology with bovine adenovirus, 604
Human cytomegalovirus
AD169
immediate-early transcripts, 363
transforming region, 109
64,000-dalton glycoprotein, 279
major immediate early gene, 190
Human hepatitis B virus
nucleotide sequence
comparison with cloned duck hepatitis B virus genome nucleotide sequence, 782
Human papovavirus
BK
rat 3Y1 cells, 78
viral early functions, 78
Hybridization
in situ
simian virus 40, 445

Influenza virus
A
antigen, 248
matrix protein, 248
monoclonal antibodies, 248
mutant with deletion in NS segment, 418
A/USSR/90/77
hemagglutinin gene nucleotide sequence, 276
hemagglutinin
altered hydrophobic carboxy terminus, 223
intracellular accumulation, 223
interferon
macrophages, 709
mouse α, 709
mouse β, 709
resistance gene *Mx*, 709
macrophages
mouse α interferon, 709
mouse β interferon, 709
resistance gene *Mx*, 709
membrane protein
phosphoprotein, 229
two forms, 229
mouse α interferon
macrophages, 709
resistance gene *Mx*, 709
mouse β interferon
macrophages, 709
resistance gene *Mx*, 709
resistance gene *Mx*
macrophages, 709
mouse α interferon, 709
mouse β interferon, 709
vaccine
human peripheral blood mononuclear cells, 748
interferon, 748
2-5A synthetase activity, 748
Insect iridescent virus
6
circular permutation, 609
terminal redundancy, 609
Interferon
E. coli-derived
human alpha, 490
human beta, 490
human gamma, 490
synergistic antiviral and antiproliferative activities, 490
human alpha
E. coli-derived, 490
synergistic antiviral and antiproliferative activities, 490
human beta
E. coli-derived, 490
synergistic antiviral and antiproliferative activities, 490
human gamma
E. coli-derived, 490
synergistic antiviral and antiproliferative activities, 490
influenza virus vaccine
human peripheral blood mononuclear cells, 748
2-5A synthetase activity, 748
mouse α
influenza virus, 709
macrophages, 709
resistance gene *Mx*, 709
mouse β
influenza virus, 709
macrophages, 709
resistance gene *Mx*, 709
rubella virus vaccine
human peripheral blood mononuclear cells, 748
2-5A synthetase activity, 748

JC virus
brain tumors
owl monkeys, 848
owl monkeys
brain tumors, 848

Kilham rat virus
structural proteins
sequency homology, 1018
Kinase
Rous sarcoma virus p60^{src}
tumor formation, 325

La Crosse virus
small-genome transcripts, 680
Ligase
polyomavirus minichromosomes, 333
Liposomes
encapsulation
retrovirus, 269
Lymphocytes
cytotoxic T
herpes simplex virus type 2, 766
lysis of herpes simplex virus-infected target cells, 766
Lymphomas
mouse T-cell
endogenous mouse mammary tumor virus genomes, 92

Macrophages
influenza virus
resistance gene *Mx*, 709
resistance gene *Mx*
influenza virus, 709
Mammalian reovirus
bovine
tryptic peptide analysis of outer capsid polypeptides, 641
genetic diversity in natural populations, 641
human type 1
tryptic peptide analysis of outer capsid polypeptides, 641
human type 3
tryptic peptide analysis of outer capsid polypeptides, 641
murine
tryptic peptide analysis of outer capsid polypeptides, 641
Marek's disease virus
glycoproteins
monoclonal antibodies, 1014
virus neutralization, 1014
monoclonal antibodies
glycoproteins, 1014
virus neutralization, 1014
virus neutralization
glycoproteins, 1014
monoclonal antibodies, 1014
Measles virus
antibody
polypeptides, 409
complicated infections, 409
intracellular nucleocapsid RNA, 57
polypeptides
antibody, 409
human cellular immune response, 988
uncomplicated infections, 409
Methylation
bacteriophage ϕX174 replicative-form DNA

transfecting activity, 674
mouse mammary tumor virus proviral DNA, 66
Methyltransferase
DNA
E. coli virus T1, 588
frog virus 3, 86
Mice
BALB/c
chromosomes 6 and 12, 1005
mouse mammary tumor virus, 1005
chromosome 6
c-*raf* oncogene, 297
C3H/Sm
mouse mammary tumor virus, 819
H-2 congenic
Gross virus, 14
tumor cell lines, 14
α interferon
influenza virus, 709
macrophages, 709
resistance gene *Mx*, 709
β interferon
influenza virus, 709
macrophages, 709
resistance gene *Mx*, 709
normal tissues
mouse mammary tumor virus, 66
plasmacytoma
intracisternal A-particle genes, 171
simian virus 40
tumor induction, 540
T-cell lymphomas
endogenous mouse mammary tumor virus genomes, 92
tumor induction
simian virus 40, 540
Minichromosomes
polyomavirus
DNA ligase activity, 333
DNA topoisomerase II activity, 333
Mink cell focus-forming murine leukemia virus
endogenous nonecotropic parent
gp70 sequence, 530
envelope gene sequence, 530
gp70 sequence
endogenous nonecotropic parent, 530
Mink cell focus-forming viruses
Friend murine leukemia virus
recombination with specific endogenous proviral sequences, 772
Minute virus of mice
metastable, partially replicated dimeric intermediate, 621
Mitogens
Rous sarcoma virus $p60^{src}$
tumor formation, 325
Mitomycin C
B. subtilis proteins, 806
ml murine sarcoma virus
transforming gene
nucleotide sequence, 579
Moloney murine leukemia virus
gag gene mutations
effects on reverse transcriptase, 918
effects on virions, 918
gag protein P12 mutations
blocking of early stages of infection, 909
gag protein P15 mutations
blocking of early stages of infection, 909
pMLV-1 noninfectious molecular clone
restoration of infectivity, 214
reverse transcriptase
gag gene mutations, 918
virions
gag gene mutations, 918
Moloney murine sarcoma virus
long terminal repeat
enhancer elements, 183
Monkeys
owl
brain tumors, 848
JC virus, 848
Mouse mammary tumor virus
BALB/c mice
chromosomes 6 and 12, 1005
genomes, 1005
C3H/Sm mice
indigenous proviral long terminal repeat-containing transcript, 819
endogenous
amplification of genomes, 92
mouse T-cell lymphomas, 92
novel locations of genomes, 92
endogenous ecotropic
DNA transfection assays, 437
molecularly cloned proviruses, 437
poorly infectious DNAs, 437
genomes
BALB/c mice, 1005
chromosomes 6 and 12, 1005
indigenous proviral long terminal repeat-containing transcript
C3H/Sm mice, 819
increased concentration in C3H/Sm mice, 819
neoplastic transformation of mammary epithelium in C3H/Sm mice, 819
normal mouse tissues
proviral DNA methylation patterns, 66
proviral DNA methylation patterns
normal mouse tissues, 66
Mycobacterium tuberculosis
inactivated
caprine arthritis-encephalitis lentivirus, 349
neutralizing antibodies, 349
persistently infected goats, 349
Mycoplasma virus
L2
novobiocin, 283
replication, 283
Myeloproliferative sarcoma virus
fibroblast transformation
temperature-sensitive mutants, 253
hematopoietic transformation
temperature-sensitive mutants, 253
temperature-sensitive mutants
fibroblast transformation, 253
hematopoietic transformation, 253

Neurons
rat sensory
herpes simplex virus genome, 205
Novobiocin
mycoplasma virus L2 replication, 283

Oncogenes
c-*raf*
mouse chromosome 6, 297
c-*rel* (turkey)
reticuloendotheliosis virus strain T, 521
structure and dimorphism, 521

Parvovirus
endogenous LuIII
minus-strand DNA encapsidation, 319
plus-strand DNA encapsidation, 319
Plasmacytoma
mouse
intracisternal A-particle genes, 171
Poliovirus
nonneutralizing, monoclonal antibodies
intertypic cross-reactions, 1002
protein processing map, 873
Polymerase
DNA
herpes simplex virus, 236
mapping, 72
transcriptional mapping, 125
vaccinia virus, 72, 125
DNA α
herpes simplex virus, 598
RNA
infected HeLa cell nuclei, 26
vaccinia virus, 26
Polyomavirus
cell transformation
impaired by deletion at DNA origin of replication, 984
viable mutants cold sensitive for maintenance, 799
deletion at DNA origin of replication
ability to form tandem insertions impaired, 984
ability to transform cells impaired, 984
DNA ligase activity
minichromosomes, 333
DNA topoisomerase II activity
minichromosomes, 333
Friend erythroleukemic cells
growth, 566
persistence, 566
growth in Friend erythroleukemic cells, 566
large T antigen
binding to DNA sequences in common with those of simian virus 40 large T antigen, 925
minichromosomes
DNA ligase activity, 333
DNA topoisomerase II activity, 333
persistence in Friend erythroleukemic cells, 566
tandem insertion formation
impaired by deletion at DNA origin of replication, 984
viable mutants
cold sensitive for maintenance of cell transformation, 799
Pseudomonas aeruginosa
PAO
bacteriophage PS17, 310
pyocin R2, 310
Pseudorabies virus
vaccine strains
deletions in genomes, 970
four isomers of genomes, 970

Pyocin
R2
bacteriophage PS17, 310
P. aeruginosa PAO, 310

Radioimmunoassays
site-specific
woodchuck hepatitis virus surface antigen, 701
Rats
3Y1 cells
human papovavirus BK, 78
Rauscher spleen focus-forming virus
membrane glycoprotein mutations
reduced leukemogenicity, 394
reduced leukemogenicity
membrane glycoprotein mutations, 394
Receptors
coxsackievirus B3, 635
Respiratory syncytial virus
assignment of polypeptides to 10 viral genes, 572
tenth mRNA, 572
Restriction endonuclease
adenovirus 5 fragments, 162
*Bgl*II
herpes simplex virus type 2 N fragment, 724
*Eco*RI
7.1-kilobase fragment, 510
vaccinia virus DNA fragment, 497, 510
Reticuloendotheliosis virus
strain T
c-*rel* (turkey) structure and dimorphism, 521
oncogene, 521
Retrovirus
liposome encapsulation
efficient superinfection of resistant cell lines, 269
Reverse transcriptase
avian myeloblastosis virus
RNA primer removal, 686
RNase H activity, 686
Moloney murine leukemia virus
gag gene mutations, 918
Ribonucleotide reductase
herpes simplex virus type 1 polypeptides, 591
herpes simplex virus type 2 polypeptides, 591
RNase H
avian myeloblastosis virus reverse transcriptase
RNA primer removal, 686
Rous-associated virus-2
noncoding regions
conserved regions important in replication and oncogenesis, 557
nucleotide sequence, 557
Rous sarcoma virus
Bryan high-titer strain
DNA sequence, 549
extent of *env* deletion, 549
genealogical relationship with other strains, 549
$p60^{src}$ kinase activity
tumor formation, 325
$p60^{src}$ mitogenic property
tumor formation, 325
tumor formation
$p60^{src}$ kinase activity, 325
$p60^{src}$ mitogenic property, 325
Rubella virus
40S genome RNA
precursor to structural proteins, 403
24S subgenomic RNA, 403
structural proteins
precursor, 403
vaccine
human peripheral blood mononuclear cells, 748
interferon, 748
2-5A synthetase activity, 748

Sendai virus
adsorbed virus particles
cell membranes, 1009
dissociation with dithiothreitol, 1009
cell membranes
adsorbed virus particles, 1009
dithiothreitol
dissociation of adsorbed virus particles, 1009
Serial affinity chromatography
varicella-zoster virus glycoprotein gp118, 992
Simian rotavirus SA11
temperature-sensitive mutants
morphogenesis, 665
protein synthesis, 665
Simian virus 40
A protein
binding to DNA, 9
chromosomal sites of integration
DNA sequences, 445
cold-sensitive transformant
large-T-antigen–p53 complex, 997
mutant *tsA*1499, 997
DNA
binding to A protein, 9
deletions at origin of replication, 9
DNA sequences
chromosomal sites of integration, 445
in situ hybridization
transformed hybrid cell lines, 445
integrated viral sequences
two types of deletion, 479
large T antigen
binding to DNA sequences in common with those of polyomavirus large T antigen, 925
oligomerization, 658
temperature-sensitive *A* gene lesions, 658
large-T-antigen–p53 complex
cold-sensitive transformant, 997
mutant *tsA*1499, 997
large tumor antigen
transformed cell surfaces, 50
mice
immune response of host, 540
long-term persistence of viral genome, 540
tumor induction, 540
mutant *tsA*1499
cold-sensitive transformant, 997
large-T-antigen–p53 complex, 997
p53 cellular protein
transformed cell surfaces, 50
reversal of theophylline resistance
small-t antigen, 262
small-t antigen
reversal of theophylline resistance, 262
T antigens
mutant, 386
relaxed specificity for viral DNA origin of replication nucleotide sequence, 386
viral DNA origin of replication nucleotide sequence, 386
transformed cell surfaces
large tumor antigen, 50
p53 cellular protein, 50
transformed hybrid cell lines
in situ hybridization, 445
transformed mouse cells
reversion, 479
tumor induction
immune response of host, 540
long-term persistence of viral genome, 540
mice, 540
Sindbis virus
defective-interfering RNAs
common regions, 865
distinct regions, 865
E1 glycoprotein
immunologically cross-reactive proteins, 379
unique conformation, 379
immunologically cross-reactive proteins
unique conformation of E1 glycoprotein, 379
Sodium butyrate
Epstein-Barr virus
DNase activity, 626
2-5A Synthetase
influenza virus vaccine
human peripheral blood mononuclear cells, 748
interferon, 748
rubella virus vaccine
human peripheral blood mononuclear cells, 748
interferon, 748

12-*O*-Tetradecanoylphorbol-13-acetate
Epstein-Barr virus
DNase activity, 626
Theophylline
simian virus 40 small-t antigen
reversal of resistance, 262
Topoisomerase
type I
effects of ATP, 1
vaccinia virus, 1
type II
polyomavirus minichromosomes, 333
Turkeys
herpesvirus
glycoproteins, 1014
monoclonal antibodies, 1014
virus neutralization, 1014

UV irradiation
herpes simplex virus
DNA polymerase α, 598
host cell reactivation, 598

Vaccine
influenza virus

human peripheral blood mononuclear cells, 748
interferon, 748
2-5A synthetase activity, 748
rubella virus
human peripheral blood mononuclear cells, 748
interferon, 748
2-5A synthetase activity, 748
Vaccinia virus
ATP
effects on type I topoisomerase activity, 1
DNA polymerase gene
transcriptional mapping, 125
DNA polymerase gene mapping
cell-free translation of RNA, 72
marker rescue, 72
*Eco*RI DNA fragment
7.1 kilobases, 510
late RNAs, 510
six early transcripts, 497
genome
early region, 459
mapping of gene coding for major late structural polypeptide, 371
infected HeLa cell nuclei
RNA polymerase, 26
inhibitory factors
effects on type I topoisomerase activity, 1
recombinants
expressing foreign genes, 857
RNA polymerase
infected HeLa cell nuclei, 26
type I topoisomerase activity
effects of ATP, 1
effects of inhibitory factors, 1
Varicella-zoster virus
glycoprotein gp118
purification by serial affinity chromatography, 992
serial affinity chromatography
glycoprotein gp118, 992
Vesicular stomatitis virus
defective-interfering particles
accumulation of few 3′-terminal mutations, 793
accumulation of stable 5′-terminal mutations, 793
resistant mutants, 793
mutants
accumulation of few 3′-terminal mutations, 793
accumulation of stable 5′-terminal mutations, 793
resistant to defective-interfering particles, 793
N protein
protein synthesis, 303
RNA replication, 303
protein synthesis
N protein, 303
RNA replication, 303
RNA replication
N protein, 303
protein synthesis, 303

Woodchuck hepatitis virus
nucleotide sequence
comparison with cloned duck hepatitis B virus genome nucleotide sequence, 782
site-specific radioimmunoassays
surface antigen, 701
surface antigen
site-specific radioimmunoassays, 701